AbbVie is one of the world’s leading pharmaceutical companies.
AbbVie delivered one of the most impressive post-patent cliff recoveries in pharmaceutical history. Full year 2025 revenues reached $61.2 billion — an 8.6% increase — driven by Skyrizi at $17.6 billion and Rinvoq at $8.3 billion collectively replacing and exceeding Humira’s biosimilar-eroded revenues of $4.5 billion. The neuroscience portfolio generated $10.8 billion in 2025, growing 19.6%, making AbbVie’s neuroscience business the second largest pharmaceutical neuroscience franchise globally. AbbVie has guided to a high single-digit compound annual revenue growth rate through 2029.
This report provides comprehensive strategic intelligence on AbbVie — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. AbbVie — Key Financial Metrics 2023-2025
Table 2. AbbVie — Revenue by Therapeutic Area 2023-2025
Table 3. AbbVie — Revenue by Geography 2023-2025
Table 4. AbbVie — R&D Investment 2023-2025
Table 5. AbbVie — SWOT Analysis
Table 6. AbbVie — Key Technology Platforms
Table 7. AbbVie — Top Products by Revenue 2025
Table 8. AbbVie — Late-Stage Pipeline 2025
Table 9. AbbVie — M&A Activity 2023-2025
Table 10. AbbVie — Key Management
Table 11. AbbVie — Strategic Priorities 2025-2030
